Cancer therapy using natural ligands that target estrogen receptor beta

Chinese Journal of Natural Medicines

Volumn 13, Issue 11, 2015, Pages 801-807

  Sareddy, Gangadhara R ^a   Vadlamudi, Ratna K ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

Author keywords

ER beta agonists; Estrogen receptor; Estrogen receptor beta; Genistein; Liquiritigenin; S equol; Tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR BETA; GENISTEIN; ISOFLAVONE; LIQUIRITIGENIN; S EQUOL; UNCLASSIFIED DRUG; EQUOL; FLAVANONE DERIVATIVE; LIGAND; PLANT EXTRACT;

BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER PREVENTION; CANCER THERAPY; COLON CANCER; GLIOMA; HUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GLYCYRRHIZA; METABOLISM; NEOPLASMS; PHYTOTHERAPY; SOYBEAN;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; EQUOL; ESTROGEN RECEPTOR BETA; FLAVANONES; GENISTEIN; GLYCYRRHIZA; HUMANS; LIGANDS; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; SOYBEANS;

EID: 84955065030     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.1016/S1875-5364(15)30083-2     Document Type: Review

References (72)

1. Thomas C, Gustafsson JA The different roles of ER subtypes in cancer biology and therapy [J]. Nat Rev Cancer 2011, 11(8):597-608.
2. Nilsson S, Gustafsson JA Estrogen receptors: therapies targeted to receptor subtypes [J]. Clin Pharmacol Ther 2011, 89(1):44-55.
3. Hartman J, Edvardsson K, Lindberg K, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells [J]. Cancer Res 2009, 69(15):6100-6106.
4. Strom A, Hartman J, Foster JS, et al. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D [J]. Proc Natl Acad Sci U S A 2004, 101(6):1566-1571.
5. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation [J]. Eur J Cancer 2003, 39(9):1251-1258.
6. Palmieri C, Cheng GJ, Saji S, et al. Estrogen receptor beta in breast cancer [J]. Endocr Relat Cancer 2002, 9(1):1-13.
7. Fox EM, Davis RJ, Shupnik MA ERbeta in breast cancer-onlooker, passive player, or active protector? [J]. Steroids 2008, 73(11):1039-1051.
8. Treeck O, Pfeiler G, Mitter D, et al. Estrogen receptor 1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells [J]. J Endocrinol 2007, 193(3):421-433.
9. Haldosen LA, Zhao C, Dahlman-Wright K Estrogen receptor beta in breast cancer [J]. Mol Cell Endocrinol 2014, 382(1):665-672.
10. Sareddy GR, Nair BC, Gonugunta VK, et al. Therapeutic significance of estrogen receptor beta agonists in gliomas [J]. Mol Cancer Ther 2012, 11(5):1174-1182.
11. Omoto Y, Iwase H Clinical significance of estrogen receptor beta in breast and prostate cancer from biological aspects [J]. Cancer Sci 2015, 106(4):337-343.
12. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary [J]. Proc Natl Acad Sci U S A 1996, 93(12):5925-5930.
13. Pettersson K, Gustafsson JA Role of estrogen receptor beta in estrogen action [J]. Annu Rev Physiol 2001, 63:165-192.
14. Couse JF, Lindzey J, Grandien K, et al. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse [J]. Endocrinology 1997, 138(11):4613-4621.
15. Grober OM, Mutarelli M, Giurato G, et al. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation [J]. BMC Genomics 2011, 12:36.
16. Charn TH, Liu ET, Chang EC, et al. Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection [J]. Mol Endocrinol 2010, 24(1):47-59.
17. Nakajima Y, Akaogi K, Suzuki T, et al. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERbeta and KLF5 [J]. Sci Signal 2011, 4(168):ra22.
18. Leung YK, Mak P, Hassan S, et al. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling [J]. Proc Natl Acad Sci U S A 2006, 103(35):13162-13167.
19. Gong P, Madak-Erdogan Z, Li J, et al. Transcriptomic analysis identifies gene networks regulated by estrogen receptor alpha (ERalpha) and ERbeta that control distinct effects of different botanical estrogens [J]. Nucl Recept Signal 2014, 12:e001.
20. Lo R, Matthews J A new class of estrogen receptor beta-selective activators [J]. Mol Interv 2010, 10(3):133-136.
21. Cvoro A, Paruthiyil S, Jones JO, et al. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract [J]. Endocrinology 2007, 148(2):538-547.
22. Grady D, Sawaya GF, Johnson KC, et al. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial [J]. Menopause 2009, 16(3):458-465.
23. Stovall DW, Pinkerton JV MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women [J]. Curr Opin Investig Drugs 2009, 10(4):365-371.
24. Mersereau JE, Levy N, Staub RE, et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist [J]. Mol Cell Endocrinol 2008, 283(1-2):49-57.
25. Jiang Y, Gong P, Madak-Erdogan Z, et al. Mechanisms enforcing the estrogen receptor beta selectivity of botanical estrogens [J]. FASEB J 2013, 27(11):4406-4418.
26. Adlercreutz H Phyto-oestrogens and cancer [J]. Lancet Oncol 2002, 3(6):364-373.
27. de Souza PL, Russell PJ, Kearsley JH, et al. Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer [J]. Nutr Rev 2010, 68(9):542-555.
28. Messina M, Nagata C, Wu AH Estimated Asian adult soy protein and isoflavone intakes [J]. Nutr Cancer 2006, 55(1):1-12.
29. Tham DM, Gardner CD, Haskell WL Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence [J]. J Clin Endocrinol Metab 1998, 83(7):2223-2235.
30. Chang EC, Charn TH, Park SH, et al. Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding [J]. Mol Endocrinol 2008, 22(5):1032-1043.
31. Pons DG, Nadal-Serrano M, Blanquer-Rossello MM, et al. Genistein modulates proliferation and mitochondrial functionality in breast cancer cells depending on ERalpha/ERbeta ratio [J]. J Cell Biochem 2014, 115(5):949-958.
32. Setchell KD, Clerici C, Lephart ED, et al. S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora [J]. Am J Clin Nutr 2005, 81(5):1072-1079.
33. Jackson RL, Greiwe JS, Schwen RJ Emerging evidence of the health benefits of S-equol, an estrogen receptor beta agonist [J]. Nutr Rev 2011, 69(8):432-448.
34. Aso T, Uchiyama S, Matsumura Y, et al. A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women [J]. J Womens Health (Larchmt) 2012, 21(1):92-100.
35. Nair HB, Kirma NB, Ganapathy M, et al. Estrogen receptor-beta activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy [J]. Steroids 2011, 76(8):792-796.
36. Adlercreutz H Phytoestrogens and breast cancer [J]. J Steroid Biochem Mol Biol 2002, 83(1-5):113-118.
37. Hinsche O, Girgert R, Emons G, et al. Estrogen receptor beta selective agonists reduce invasiveness of triple-negative breast cancer cells [J]. Int J Oncol 2015, 46(2):878-884.
38. Magee PJ, Allsopp P, Samaletdin A, et al. Daidzein, R-(+)equol and S-(-)equol inhibit the invasion of MDA-MB-231 breast cancer cells potentially via the down-regulation of matrix metalloproteinase-2 [J]. Eur J Nutr 2014, 53(1):345-350.
39. Charalambous C, Pitta CA, Constantinou AI Equol enhances tamoxifen's anti-tumor activity by induction of caspase-mediated apoptosis in MCF-7 breast cancer cells [J]. BMC Cancer 2013, 13:238.
40. Onoda A, Ueno T, Uchiyama S, et al. Effects of S-equol and natural S-equol supplement (SE5-OH) on the growth of MCF-7 in vitro and as tumors implanted into ovariectomized athymic mice [J]. Food Chem Toxicol 2011, 49(9):2279-2284.
41. Yang X, Belosay A, Hartman JA, et al. Dietary soy isoflavones increase metastasis to lungs in an experimental model of breast cancer with bone micro-tumors [J]. Clin Exp Metastasis 2015, 32(4):323-333.
42. Jarred RA, Keikha M, Dowling C, et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones [J]. Cancer Epidemiol Biomarkers Prev 2002, 11(12):1689-1696.
43. McPherson SJ, Hussain S, Balanathan P, et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated [J]. Proc Natl Acad Sci U S A 2010, 107(7):3123-3128.
44. Thelen P, Wuttke W, Seidlova-Wuttke D Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer [J]. J Steroid Biochem Mol Biol 2014, 139:290-293.
45. Mahmoud AM, Al-Alem U, Ali MM, et al. Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation [J]. J Steroid Biochem Mol Biol 2015, 152:62-75.
46. Hatch EE, Linet MS, Zhang J, et al. Reproductive and hormonal factors and risk of brain tumors in adult females [J]. Int J Cancer 2005, 114(5):797-805.
47. Huang K, Whelan EA, Ruder AM, et al. Reproductive factors and risk of glioma in women [J]. Cancer Epidemiol Biomarkers Prev 2004, 13(10):1583-1588.
48. Kabat GC, Etgen AM, Rohan TE Do steroid hormones play a role in the etiology of glioma? [J]. Cancer Epidemiol Biomarkers Prev 2010, 19(10):2421-2427.
49. Kabat GC, Park Y, Hollenbeck AR, et al. Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP diet and health study [J]. Int J Cancer 2011, 128(4):944-950.
50. Michaud DS, Gallo V, Schlehofer B, et al. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study [J]. Cancer Epidemiol Biomarkers Prev 2010, 19(10):2562-2569.
51. Carroll RS, Zhang J, Dashner K, et al. Steroid hormone receptors in astrocytic neoplasms [J]. Neurosurgery 1995, 37(3):496-503.
52. Batistatou A, Stefanou D, Goussia A, et al. Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm [J]. J Cancer Res Clin Oncol 2004, 130(7):405-410.
53. Batistatou A, Kyzas PA, Goussia A, et al. Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours [J]. J Neurooncol 2006, 77(1):17-23.
54. Li W, Winters A, Poteet E, et al. Involvement of estrogen receptor beta5 in the progression of glioma [J]. Brain Res 2013, 1503:97-107.
55. Liu X, Wang L, Chen J, et al. Estrogen receptor beta agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway [J]. Mol Med Rep 2015, 11(2):1516-1522.
56. Akhter M, Inoue M, Kurahashi N, et al. Dietary soy and isoflavone intake and risk of colorectal cancer in the Japan public health center-based prospective study [J]. Cancer Epidemiol Biomarkers Prev 2008, 17(8):2128-2135.
57. Rudolph A, Toth C, Hoffmeister M, et al. Expression of oestrogen receptor beta and prognosis of colorectal cancer [J]. Br J Cancer 2012, 107(5):831-839.
58. Bielecki A, Roberts J, Mehta R, et al. Estrogen receptor-beta mediates the inhibition of DLD-1 human colon adenocarcinoma cells by soy isoflavones [J]. Nutr Cancer 2011, 63(1):139-150.
59. Weige CC, Allred KF, Allred CD Estradiol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon [J]. Cancer Res 2009, 69(23):9118-9124.
60. Hartman J, Edvardsson K, Lindberg K, et al. Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells [J]. Cancer Res 2009, 69(15):6100-6106.
61. Schleipen B, Hertrampf T, Fritzemeier KH, et al. ERbeta-specific agonists and genistein inhibit proliferation and induce apoptosis in the large and small intestine [J]. Carcinogenesis 2011, 32(11):1675-1683.
62. Pampaloni B, Palmini G, Mavilia C, et al. In vitro effects of polyphenols on colorectal cancer cells [J]. World J Gastrointest Oncol 2014, 6(8):289-300.
63. Landen CN, Birrer MJ, Sood AK Early events in the pathogenesis of epithelial ovarian cancer [J]. J Clin Oncol 2008, 26(6):995-1005.
64. Ozols RF, Bookman MA, Connolly DC, et al. Focus on epithelial ovarian cancer [J]. Cancer Cell 2004, 5(1):19-24.
65. Chan KK, Leung TH, Chan DW, et al. Targeting estrogen receptor subtypes (ERalpha and ERbeta) with selective ER modulators in ovarian cancer [J]. J Endocrinol 2014, 221(2):325-336.
66. Sareddy GR Chavez JE SHMMHJKSKETRVR. Therapeutic efficacy of ERß agonists on ovarian cancer [J]. Cancer Res 2014, 74(19 Suppl). Abstract nr 606. ed.
67. Wang Y, Xie S, Liu C, et al. Inhibitory effect of liquiritigenin on migration via downregulation proMMP-2 and PI3K/Akt signaling pathway in human lung adenocarcinoma A549 cells [J]. Nutr Cancer 2012, 64(4):627-634.
68. Wang D, Lu J, Liu Y, et al. Liquiritigenin induces tumor cell death through mitogen-activated protein kinase-(MPAKs-) mediated pathway in hepatocellular carcinoma cells [J]. Biomed Res Int 2014, 2014:965316.
69. Zhou M, Higo H, Cai Y Inhibition of hepatoma 22 tumor by Liquiritigenin [J]. Phytother Res 2010, 24(6):827-833.
70. Liang XL, Li M, Li J, et al. Equol induces apoptosis in human hepatocellular carcinoma SMMC-7721 cells through the intrinsic pathway and the endoplasmic reticulum stress pathway [J]. Anticancer Drugs 2014, 25(6):633-640.
71. Shi H, Wu Y, Wang Y, et al. Liquiritigenin potentiates the inhibitory effects of cisplatin on invasion and metastasis via downregulation MMP-2/9 and PI3 K/AKT signaling pathway in B16F10 melanoma cells and mice model [J]. Nutr Cancer 2015, 1-10.
72. Wang D, Wong HK, Feng YB, et al. Liquiritigenin exhibits antitumour action in pituitary adenoma cells via Ras/ERKs and ROS-dependent mitochondrial signalling pathways [J]. J Pharm Pharmacol 2014, 66(3):408-417.